Modulating biomolecular condensates: a novel approach to drug discovery.

Autor: Mitrea DM; Dewpoint Therapeutics, Boston, MA, USA., Mittasch M; Dewpoint Therapeutics, Dresden, Germany., Gomes BF; Dewpoint Therapeutics, Dresden, Germany., Klein IA; Dewpoint Therapeutics, Boston, MA, USA. iklein@dewpointx.com., Murcko MA; Dewpoint Therapeutics, Boston, MA, USA. mmurcko@dewpointx.com.
Jazyk: angličtina
Zdroj: Nature reviews. Drug discovery [Nat Rev Drug Discov] 2022 Nov; Vol. 21 (11), pp. 841-862. Date of Electronic Publication: 2022 Aug 16.
DOI: 10.1038/s41573-022-00505-4
Abstrakt: In the past decade, membraneless assemblies known as biomolecular condensates have been reported to play key roles in many cellular functions by compartmentalizing specific proteins and nucleic acids in subcellular environments with distinct properties. Furthermore, growing evidence supports the view that biomolecular condensates often form by phase separation, in which a single-phase system demixes into a two-phase system consisting of a condensed phase and a dilute phase of particular biomolecules. Emerging understanding of condensate function in normal and aberrant cellular states, and of the mechanisms of condensate formation, is providing new insights into human disease and revealing novel therapeutic opportunities. In this Perspective, we propose that such insights could enable a previously unexplored drug discovery approach based on identifying condensate-modifying therapeutics (c-mods), and we discuss the strategies, techniques and challenges involved.
(© 2022. Springer Nature Limited.)
Databáze: MEDLINE
Externí odkaz: